To evaluate the effectiveness of a therapeutic trial of valganciclovir in patients with uveitis with positive Epstein-Barr virus early antigen D immunoglobulin G titers (EBV EA-D).
Methods
We performed a retrospective chart review of 14 patients at the Massachusetts Eye Research and Surgery Institution who had uveitis with positive EBV EA-D but negative studies for all other causes of uveitis and were treated with valganciclovir 450 mg twice a day or valganciclovir 900 mg twice a day between January 2010 and August 2014.
Results
Nine of 14 patients, who had presumed EBV reactivation with associated intraocular inflammation, were successfully treated with valganciclovir: 3 of these were treated with valganciclovir 450 mg twice a day and 6 were treated with valganciclovir 900 mg twice a day. Five of 14 patients failed to respond to valganciclovir with persistent inflammation after at least 2 weeks of valganciclovir therapy, and were subsequently treated with immunomodulatory therapy to control inflammation.
Conclusions
Uveitis can be caused by EBV infection/reactivation. A therapeutic trial with valganciclovir 450 mg twice a day for 1 month in patients with uveitis with positive EBV EA antibody may be beneficial.
CohenJIEpstein-Barr virus infection. N Engl J Med2000343481–92.
2.
CohenJIFauciASVarmusHNabelGJEpstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med20113107fs7.
3.
KimuraHKawadaJItoYEpstein-Barr virus-associated lymphoid malignancies: the expanding spectrum of hematopoietic neoplasms. Nagoya J Med Sci201375169–79.
4.
CoghillAEHildesheimAEpstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. Am J Epidemiol2014180687–95.
5.
PeponisVGChatziralliIPParikakisEAChairaNKatzakisMCMitropoulosPGBilateral multifocal chorioretinitis and optic neuritis due to Epstein-Barr virus: a case report. Case Rep Ophthalmol20123327–32.
6.
OstlerHBThygesonPThe ocular manifestations of herpes zoster, varicella, infectious mononucleosis, and cytomegalovirus disease. Surv Ophthalmol197621148–59.
7.
SugiyamaKItoMIchimiRA case of Epstein-Barr virus infection with exophthalmos and ocular muscle swelling. Acta Paediatr Jpn199739694–7.
8.
WongKWD'AmicoDJHedgesTRIIISoongHKSchooleyRTKenyonKROcular involvement associated with chronic Epstein-Barr virus disease. Arch Ophthalmol1987105788–92.
9.
HenleWHenleGEpstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res1981414222–5.
10.
GulleyMLMolecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn200131–10.
11.
AnderssonJBrittonSErnbergIEffect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis1986153283–90.
12.
PaganoJSSixbeyJWLinJCAcyclovir and Epstein-Barr virus infection. J Antimicrob Chemother198312Suppl B113–21.
13.
SullivanJLByronKSBrewsterFESakamotoKShawJEPaganoJSTreatment of life-threatening Epstein-Barr virus infection with acyclovir. Am J Med198273262–6.
14.
ColbyBMShawJEElionGBPaganoJSEffect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol198034560–8.
15.
PayaCHumarADominguezE; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant20044611–20.
16.
StewartMWOptimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol20104285–99.
17.
PisapiaRMarianoARiandaATestaAOlivaAVincenziLSevere EBV hepatitis treated with valganciclovir. Infection201341251–4.
18.
VenturiCBuenoJGavaldaJImpact of valganciclovir on Epstein-Barr virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant Proc2009411038–40.
19.
CauldwellKWilliamsRUnusual presentation of Epstein-Barr virus hepatitis treated successfully with valganciclovir. J Med Virol201486484–6.
20.
HierroLDíez-DoradoRDíazCEfficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl2008141185–93.
21.
KogelnikAMLoomisKHoegh-PetersenMRossoFHischierCMontoyaJGUse of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol200637Suppl 1S33–8.
22.
KluttsJSFordBAPerezNRGronowskiAMEvidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol2009473204–10.
SlobodKSSandlundJTSpiegelPHMolecular evidence of ocular Epstein-Barr virus infection. Clin Infect Dis200031184–8.
25.
MittraRAPulidoJSHansonGAKajdacsy-BallaABrummittCFPrimary ocular Epstein-Barr virus-associated non-Hodgkin's lymphoma in a patient with AIDS: a clinicopathologic report. Retina19991945–50.
26.
YehSForooghianFSuhlerEBImplications of the Pacific Ocular Inflammation Uveitis Epidemiology Study. JAMA20143111912–3.
27.
AcharyaNRThamVMEsterbergEIncidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol20131311405–12.
28.
MatobaAYOcular disease associated with Epstein-Barr virus infection. Surv Ophthalmol199035145–50.
29.
OngkosuwitoJVVan der LelijABruinenbergMIncreased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis. Br J Ophthalmol199882245–51.
30.
CrouseCAPflugfelderSCClearyTDemickSMAthertonSSDetection of Epstein-Barr virus genomes in normal human lacrimal glands. J Clin Microbiol1990281026–32.
31.
ChodoshJGanYJSixbeyJWDetection of Epstein-Barr virus genome in ocular tissues. Ophthalmology1996103687–90.
32.
Lee-WingMWHodgeWGDiaz-MitomaFThe prevalence of herpes family virus DNA in the conjunctiva of patients positive and negative for human immunodeficiency virus using the polymerase chain reaction. Ophthalmology1999106350–4.
33.
YamamotoSSugitaSSugamotoYShimizuNMorioTMochizukiMQuantitative PCR for the detection of genomic DNA of Epstein-Barr virus in ocular fluids of patients with uveitis. Jpn J Ophthalmol200852463–7.
34.
TougeCAgawaHSairenjiTInoueYHigh incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis. Arch Virol2006151895–903.
35.
FieldHJVere HodgeRARecent developments in anti-herpesvirus drugs. Br Med Bull2013106213–49.
36.
VouloumanouEKRafailidisPIFalagasMECurrent diagnosis and management of infectious mononucleosis. Curr Opin Hematol20121914–20.
37.
SahinAHamrahPAcute herpetic keratitis: what is the role for ganciclovir ophthalmic gel?Ophthalmol Eye Dis2012423–34.
38.
CheeSPJapACytomegalovirus anterior uveitis: outcome of treatment. Br J Ophthalmol2010941648–52.
39.
ChouTYHongBYGanciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag201410665–81.
40.
YangEVWebster MarketonJIChenMLoKWKimSJGlaserRGlucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression. Brain Behav Immun2010241089–96.
